Judah Folkman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Judah Folkman has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Arja Kaipainen
Vascular Biology Program, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115
2 shared publicationsCarmen M. Barnés
Vascular Biology Program, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115
2 shared publicationsCatherine E. Butterfield
Vascular Biology Program, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115
2 shared publications- Mark William Kieran
Bristol Myers Squibb, USA
2 shared publications Sui Huang
Vascular Biology Program, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115
2 shared publicationsA. Lindsay Frazier
1 shared publication
Latest Publications
- 1 January 2014
- Published by Springer Nature
- p. 1412-1417
Dormancy
- 1 January 2014
- Published by Springer Nature
- p. 1-6
Dormancy
- 10 June 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 409 (3) , 562-566
Beta-35 is a transferrin-derived inhibitor of angiogenesis and tumor growth
- 10 June 2011
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 409 (3) , 562-566
Beta-35 is a transferrin-derived inhibitor of angiogenesis and tumor growth
- 1 January 2011
- Published by Springer Nature
- p. 1151-1154
Dormancy
- 1 January 2009
- Published by Elsevier
Contributors
- 22 January 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (3) , 985-990
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)α deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPARα would promote tumor growth. Surprisingly, the PPARα agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPARα-deficient tumors were still susceptible to fenofibrate, absence of PPARα in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPARα as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPARα agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARα agonists in cancer treatment, alone and in combination with other therapies.
- 22 January 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (3) , 985-990
PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
Angiogenesis and inflammation are central processes through which the tumor microenvironment influences tumor growth. We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)α deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of PPARα would promote tumor growth. Surprisingly, the PPARα agonist fenofibrate potently suppressed primary tumor growth in mice. This effect was not mediated by cancer-cell-autonomous antiproliferative mechanisms but by the inhibition of angiogenesis and inflammation in the host tissue. Although PPARα-deficient tumors were still susceptible to fenofibrate, absence of PPARα in the host animal abrogated the potent antitumor effect of fenofibrate. In addition, fenofibrate suppressed endothelial cell proliferation and VEGF production, increased TSP-1 and endostatin, and inhibited corneal neovascularization. Thus, both genetic abrogation of PPARα as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways. These findings reveal the potential utility of the well tolerated PPARα agonists beyond their use as lipid-lowering drugs in anticancer therapy. Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARα agonists in cancer treatment, alone and in combination with other therapies.
- Open Access
- 31 July 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (31) , 12890-12895
Transcriptional network governing the angiogenic switch in human pancreatic cancer
A shift of the angiogenic balance to the proangiogenic state, termed the “angiogenic switch,” is a hallmark of cancer progression. Here we devise a strategy for identifying genetic participants of the angiogenic switch based on inverse regulation of genes in human endothelial cells in response to key endogenous pro- and antiangiogenic proteins. This approach reveals a global network pattern for vascular homeostasis connecting known angiogenesis-related genes with previously unknown signaling components. We also demonstrate that the angiogenic switch is governed by simultaneous regulations of multiple genes organized as transcriptional circuitries. In pancreatic cancer patients, we validate the transcriptome-derived switch of the identified “angiogenic network:” The angiogenic state in chronic pancreatitis specimens is intermediate between the normal (angiogenesis off) and neoplastic (angiogenesis on) condition, suggesting that aberrant proangiogenic environment contributes to the increased cancer risk in patients with chronic pancreatitis. In knockout experiments in mice, we show that the targeted removal of a hub node (peroxisome proliferative-activated receptor δ) of the angiogenic network markedly impairs angiogenesis and tumor growth. Further, in tumor patients, we show that peroxisome proliferative-activated receptor δ expression levels are correlated with advanced pathological tumor stage, increased risk for tumor recurrence, and distant metastasis. Our results therefore also may contribute to the rational design of antiangiogenic cancer agents; whereas “narrow” targeted cancer drugs may fail to shift the robust angiogenic regulatory network toward antiangiogenesis, the network may be more vulnerable to multiple or broad-spectrum inhibitors or to the targeted removal of the identified angiogenic “hub” nodes.
- 31 July 2007
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (31) , 12890-12895
Open AccessTranscriptional network governing the angiogenic switch in human pancreatic cancer
A shift of the angiogenic balance to the proangiogenic state, termed the “angiogenic switch,” is a hallmark of cancer progression. Here we devise a strategy for identifying genetic participants of the angiogenic switch based on inverse regulation of genes in human endothelial cells in response to key endogenous pro- and antiangiogenic proteins. This approach reveals a global network pattern for vascular homeostasis connecting known angiogenesis-related genes with previously unknown signaling components. We also demonstrate that the angiogenic switch is governed by simultaneous regulations of multiple genes organized as transcriptional circuitries. In pancreatic cancer patients, we validate the transcriptome-derived switch of the identified “angiogenic network:” The angiogenic state in chronic pancreatitis specimens is intermediate between the normal (angiogenesis off) and neoplastic (angiogenesis on) condition, suggesting that aberrant proangiogenic environment contributes to the increased cancer risk in patients with chronic pancreatitis. In knockout experiments in mice, we show that the targeted removal of a hub node (peroxisome proliferative-activated receptor δ) of the angiogenic network markedly impairs angiogenesis and tumor growth. Further, in tumor patients, we show that peroxisome proliferative-activated receptor δ expression levels are correlated with advanced pathological tumor stage, increased risk for tumor recurrence, and distant metastasis. Our results therefore also may contribute to the rational design of antiangiogenic cancer agents; whereas “narrow” targeted cancer drugs may fail to shift the robust angiogenic regulatory network toward antiangiogenesis, the network may be more vulnerable to multiple or broad-spectrum inhibitors or to the targeted removal of the identified angiogenic “hub” nodes.
- Top Cited Papers
- 1 April 2007
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (4) , 273-286
Angiogenesis: an organizing principle for drug discovery?
Pathological angiogenesis plays a role in a wide range of diseases. Folkman argues that viewing angiogenesis as an 'organizing principle' in biology can lead to novel insights into the molecular mechanisms of seemingly unrelated phenomena, and facilitate the development of new therapeutic approaches. Angiogenesis — the process of new blood-vessel growth — has an essential role in development, reproduction and repair. However, pathological angiogenesis occurs not only in tumour formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'. By viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.
- 1 April 2007
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (4) , 273-286
Top Cited PapersAngiogenesis: an organizing principle for drug discovery?
Pathological angiogenesis plays a role in a wide range of diseases. Folkman argues that viewing angiogenesis as an 'organizing principle' in biology can lead to novel insights into the molecular mechanisms of seemingly unrelated phenomena, and facilitate the development of new therapeutic approaches. Angiogenesis — the process of new blood-vessel growth — has an essential role in development, reproduction and repair. However, pathological angiogenesis occurs not only in tumour formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'. By viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.
- 1 January 2007
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 42 (1) , 1-11
Is angiogenesis an organizing principle in biology and medicine?
- 1 January 2007
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 42 (1) , 1-11
Is angiogenesis an organizing principle in biology and medicine?
- 26 September 2006
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2006 (354) , pe35
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin
Recent research shows that p53 suppresses tumor angiogenesis by transcriptionally activating the α(II) collagen prolyl-4-hydroxylase gene. This results in the extracellular release of the potent endogenous angiogenesis inhibitors endostatin and tumstatin from collagens 18 and 4, respectively. The involvement of these inhibitors elucidates a molecular mechanism. By simultaneously repressing a multitude of proangiogenic pathways and by inducing antiangiogenic pathways, a tumor suppressor protein can prevent an incipient tumor from switching to the angiogenic phenotype. Thus, p53 guards the genome from cancer by controlling the three fundamental processes that are critical for growth of a primary tumor and its metastases—tumor cell proliferation, apoptosis, and tumor angiogenesis.
- 26 September 2006
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2006 (354) , pe35
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin
Recent research shows that p53 suppresses tumor angiogenesis by transcriptionally activating the α(II) collagen prolyl-4-hydroxylase gene. This results in the extracellular release of the potent endogenous angiogenesis inhibitors endostatin and tumstatin from collagens 18 and 4, respectively. The involvement of these inhibitors elucidates a molecular mechanism. By simultaneously repressing a multitude of proangiogenic pathways and by inducing antiangiogenic pathways, a tumor suppressor protein can prevent an incipient tumor from switching to the angiogenic phenotype. Thus, p53 guards the genome from cancer by controlling the three fundamental processes that are critical for growth of a primary tumor and its metastases—tumor cell proliferation, apoptosis, and tumor angiogenesis.